James Molloy

Edward Woo

Gene Carter

- **IGC Pharma** announced **promising in-vitro findings for IGC-1C**, a low-molecular weight compound targeting an early-stage mechanism in Alzheimer's disease by modulating the tau protein's liquid-liquid phase separation (LLPS).  **[1326205_14148f0a18eb452d9e722c917d51bb4c]** 
- **IGC-1C** can **inhibit the formation and promote the dissolution of zinc-mediated tau condensates**, reducing their size and number and preventing their conversion into toxic amyloid fibrils, as demonstrated in preclinical studies.  **[1326205_14148f0a18eb452d9e722c917d51bb4c]** 
- The company plans to **advance IGC-1C through further validation and clinical trials**, with potential expansion into other neurodegenerative disorders and cancer therapies.  **[1326205_14148f0a18eb452d9e722c917d51bb4c]** 
- Despite this scientific progress, **IGC Pharma faces financial challenges**, including negative margins and a low Altman Z-Score.  **[1326205_14148f0a18eb452d9e722c917d51bb4c]**

IGC Pharma Reports Promising Preclinical Data for Alzheimer's Treatment

- Ascendiant Capital Markets has maintained a **"Buy" rating** on IGC Pharma's stock and raised its price target from **$4.25 to $4.50**.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- IGC Pharma is a **clinical-stage biotechnology firm** developing cannabinoid-based treatments for Alzheimer’s disease, with its lead asset **IGC-AD1** currently in a Phase 2 trial.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- The company's pipeline includes other investigational drugs and it integrates **AI to accelerate drug discovery** and clinical trials.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- Analysts expect **positive clinical data and progress in 2025** to be strong catalysts for the stock.  **[1326205_92898fe448084552a83c7195b75b2cb6]** 
- IGC Pharma has filed **30 patents** and demonstrates strong liquidity with a current ratio of **1.25**, a quick ratio of **0.47**, and a low debt-to-equity ratio of **0.02**.  **[1326205_92898fe448084552a83c7195b75b2cb6]**

IGC Pharma (IGC)